First-episode schizophrenia: The importance of early intervention and subjective tolerability

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 23, 1999, Pages 5-

  Kasper, Siegfried ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; QUETIAPINE;

ARTICLE; BRAIN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; EARLY DIAGNOSIS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIALS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0342680065     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Caldwell CB, Gottesman JI. Schizophrenia: a high risk factor for suicide: clues to risk reduction. Suicide Life Threat Behav 1992;22:479-493
2. Velligan DI, Miller AL. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 1999;60(suppl 23):25-28
3. Shepherd M, Watt D Falloon I, et al. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl 1989;15:1-46
4. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993;54(3, suppl):13-17
5. McGlashan TH, Fenton WS. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 1993;19:71-84
6. Dube KC, Kumar N, Dube S. Long term course and outcome of the Agra cases in the International Pilot Study of Schizophrenia. Acta Psychiatr Scand 1984;70:170-179
7. McGlashan T. What has become of the psychotherapy of schizophrenia? Acta Psychiatr Scand 1984;90(suppl 384):147-152
8. Carpenter W, Strauss J. The prediction of outcome in schizophrenia, V: eleven year follow-up of the IPSS cohort. J Nerv Ment Dis 1991;179: 517-525
9. De Quardo JR, Tandon R. Do atypical antipsychotic medications favourably alter the long-term course of schizophrenia? J Psychiatr Res 1998;32: 229-242
10. Crow TJ, Johnstone EC, Johnson AL, et al. The Northwick Park study on first episodes of schizophrenia, II: a randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120-127
11. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1992;17:325-351
12. Linszen D, Lenior M, De Hann L, et al. Early intervention, untreated psychosis and the course of early schizophrenia. Br J Psychiatry (suppl) 1998; 172(33):84-89
13. Wyatt RJ, Green MF, Turna AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychol Med 1997;27:261-268
14. Falloon IR. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 1992;55:4-15
15. McGorry PD, Edwards J, Mihalopoulos C, et al. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996;22: 305-326
16. Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry 1998;172(suppl 33):53-59
17. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-376
18. Lieberman JA, Alvir JM, Woerner M, et al. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull 1992;18:351-371
19. Szymanski S, Lieberman JA, Alvir JM, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 1995;152:698-703
20. Baumi J, Kissling W, Buttner P, et al. Informationszentriertr patienten- und angehorigengruppen zur compliance-verbesserung hei schizophrenen psychosen. Verhaltenstherapie 1993;3(suppl 1):1-96
21. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416
22. Hellewell JSE. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999;60(suppl 23): 14-19
23. Emsley RA. Partial response to antipsychotic treatment: the patient with enduring symptoms. J Clin Psychiatry 1999;60(suppl 23):10-13
24. Buckley PF. Treatment of schizophrenia: let's talk dollars and sense. Am J Managed Care 1998;4:369-383
25. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
26. Fleischhacker W, Link C, Hurst B. ICI 204,636 (Seroquel) - a putative new antipsychotic: results from phase III trials. Schizophr Res 1996;18: 132
27. Small JG, Hirsch SR, Arvanitis LA, et al, and the Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
28. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273
29. Gerlach J. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 1999;60(suppl 23): 20-24
30. Kasper S, Tauscher J, Kufferle B, et al. IBMZ-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics. Eur Psychiatry 1998;13(suppl 1):9S-14S
31. Jones H. The use of quetiapine in first-episode schizophrenia: a case study. J Clin Psychiatry 1999;60(suppl 23):6
32. Lee KMS. Rapid relief from the symptoms of schizophrenia with quetiapine: a case study. J Clin Psychiatry 1999;60(suppl 23):8
33. Borison RL, Arvanitis LA, Miller BG, and the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-169